Evicenter
MarkdownMedical informationP&T meetings
Barzolvolimab (CDX-0159)

Chronic spontaneous urticaria

Launch
Not announced
Last updated
177 sources

Product information and disease descriptionProduct descriptionProduct informationDosing and administration

Dosage

6 evidence topics · 10 sources

Phase 3 regimens: 150 mg every 4 weeks after a 300 mg loading dose, or 300 mg every 8 weeks after a 450 mg loading dose
Dose regimen proposed for licensure

No evidence found.

Phase 2 regimens
Regimens with a 450 mg loading dose in cold urticaria, symptomatic dermographism, atopic dermatitis, and prurigo nodularis